Background The Food and Drug Administration patient-reported outcome (PRO) guidance provides standards for PRO development, but these standards bring scientific and logistical challenges which can result in a lengthy and expensive instrument development ...
Louise Humphrey +6 more
doaj +1 more source
Biomarkers of response to therapy in Ankylosing Spondylitis [PDF]
Ankylosing Spondylitis (AS) is a chronic inflammatory disorder of the spine which leads to progressive spinal fusion and deformity. With improvements in MRI, this condition is now being recognized earlier.
Pathan, Ejaz Mohammed Ishaq
core +1 more source
Evaluation of serum paraoxonase and arylesterase activities in ankylosing spondylitis patients
OBJECTIVES: The aim of this study was to investigate the activities of serum paraoxonase and arylesterase in patients with ankylosing spondylitis with respect to those of healthy controls, to assess whether these enzyme levels are related to disease ...
Fazile Hatipoglu Erdem +3 more
doaj +1 more source
Persistent clinical efficacy and safety of anti-tumour necrosis factor \textgreeka therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response [PDF]
Background: There is insufficient evidence for the long-term efficacy and safety of anti-tumour necrosis factor therapy in patients with ankylosing spondylitis (AS).
Baraliakos, X. +11 more
core +1 more source
Discovery of fecal microbial signatures in patients with ankylosing spondylitis
Objectives: This study aimed to investigate the characteristics of the gut microbiota in Chinese patients with ankylosing spondylitis (AS) and healthy controls in Quanzhou aiming to explore the correlation between microbiome changes and AS activities.
Yuquan You +6 more
doaj
Background Ankylosing spondylitis is a chronic inflammatory rheumatic disorder which usually begins in early adulthood. The diagnosis is often delayed by many years.
Hodler Juerg +4 more
doaj +1 more source
The effect of three years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study [PDF]
INTRODUCTION: The aim of this study was to investigate the effect of three years of tumor necrosis factor-alpha (TNF-alpha) blocking therapy on bone turnover as well as to analyze the predictive value of early changes in bone turnover markers (BTM) for ...
Eveline van der Veer +18 more
core +2 more sources
Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis
Background The assessment and characterization of the gut microbiome has become a focus of research in the area of human autoimmune diseases. Ankylosing spondylitis is an inflammatory autoimmune disease and evidence showed that ankylosing spondylitis may
Chengping Wen +20 more
doaj +1 more source
ASAS/EULAR recommendations for the management of ankylosing spondylitis [PDF]
Objective: To develop evidence based recommendations for the management of ankylosing spondylitis (AS) as a combined effort of the `ASsessment in AS' international working group and the European League Against Rheumatism.Methods: Each of the 22 ...
Sieper, J. +51 more
core +1 more source
ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health [PDF]
Objective: To report on the results of a standardised consensus process agreeing on concepts typical and/or relevant when classifying functioning and health in patients with ankylosing spondylitis (AS) based on the International Classification of ...
Stucki, Gerold +17 more
core +1 more source

